Pediatrics Doctors in Caribou, ME Accepting Medicare

4 Pediatrics doctors found. Showing 1 - 4

Dr. Kevin Frederick Strong, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 163 Van Buren Rd, Caribou, ME 04736 Phone: 207-492-3451    Fax: 207-498-1697

William B Brandenberger, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 163 Van Buren Rd, Caribou, ME 04736 Phone: 207-492-3451    Fax: 207-498-1392

Farhana Ahmad, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 163 Van Buren Rd, Caribou, ME 04736 Phone: 207-492-3451    Fax: 207-498-1697

Kathryn Rutledge, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 163 Van Buren Rd, Caribou, ME 04736 Phone: 207-492-3451    Fax: 207-498-1392

News Archive

EpiCept regains compliance with Nasdaq minimum bid price requirement

EpiCept Corporation today announced that Nasdaq notified the Company that it has regained compliance with the minimum bid price requirement in Listing Rule 5550(a)(2) and met the requirements of the Nasdaq Listing Qualification Panel (the "Panel") decision dated November 2, 2009. Accordingly, the Panel has determined to continue the listing of the Company's common stock on The Nasdaq Stock Market.

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

Researchers develop normalized brain growth curve charts for children

In the United States, nearly every pediatric doctor's visit begins with three measurements: weight, height and head circumference. Compared to average growth charts of children across the country, established in the 1970s, a child's numbers can confirm typical development or provide a diagnostic baseline to assess deviations from the curve.

Extra warning of blood clot risk with contraceptive skin patch

Drug regulators in the United States have granted approval for an additional warning to be added to the label of a popular contraceptive patch.

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.

Read more Medical News

› Verified 9 days ago